arrow
K

Kai Rejeski

department of medicine iii
H指数:30
被引数:3,392

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

TP53-mutant CHIP defines a pro-inflammatory phenotype and predicts adverse outcomes after CAR T-cell therapy

TP53突变型CHIP定义了促炎表型并预测CAR T细胞疗法后的不良结局

Leukemia
IF13.4
2026-08-240
OAAI
Expert Panel Review and Practical Guidance on Biomarker Testing With Engineered Immune Effector Cells

专家小组评审及工程化免疫效应细胞生物标志物检测的实用指南

2026-05-160
OAAI
Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland

德国和瑞士常规环境中,Brexucabtagene-autoleucel治疗复发/难治性套细胞淋巴瘤患者的疗效结果

2026-01-160
OAAI
Late hematologic toxicity after CAR T-cell therapy in large B-cell lymphoma: incidence, risk factors, and clinical impact

大B细胞淋巴瘤中CAR T细胞疗法后的晚期血液学毒性:发生率、危险因素及临床影响

2025-11-180
PRE
Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell Engagers

炎症为基础评分在复发/难治性LBCL患者接受CD3xCD20双特异性T细胞接合物治疗中的预后价值

2025-10-240
OAAI
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia

CAR HEMATOTOX 独立预测急性淋巴细胞白血病接受CD19 CAR-T疗法后的结局

2025-10-080
OAAI
MANAGEMENT OF IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME FOLLOWING CAR-T CELL THERAPY IN CLINICAL PRACTICE: A MULTICENTRIC, RETROSPECTIVE, REAL-WORLD ANALYSIS OF TREATMENT APPROACHES AND OUTCOMES

临床实践中CAR-T细胞疗法后免疫效应细胞相关神经毒性综合征的管理:治疗方法和结局的多中心、回顾性、真实世界分析

2025-10-010
OAAI
Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma

CD19 CAR-T在大型B细胞淋巴瘤中国际代谢预后指数的优化与验证

2025-08-260
OAAI
Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies

嵌合抗原受体T细胞疗法治疗血液系统恶性肿瘤后的体液疫苗反应

2025-07-020
OAAI
Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment

大型B细胞淋巴瘤会印刻一种功能失调的免疫表型,该表型在治疗后数年仍然持续存在。

Blood
IF23.1
2025-05-150
OAAI
Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma

桥接强度与多发性骨髓瘤患者接受BCMA CAR-T疗法后的造血恢复受损相关

2025-04-250
OAAI
Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy

结外受累的大B细胞淋巴瘤的位点特异性分析揭示了嵌合抗原受体T细胞疗法的独特疗效

LEUKEMIA
IF13.4
2025-04-010
PRE